News

The court ruled in Pfizer’s favor in a lawsuit brought by the pharmaceutical giant against the generic manufacturer Ranbaxy. As a result of the decision, Pfizer will be

The combination of Berna and Chiron would offer complementary geographic coverage and product ranges. Novartis would also gain access to Berna’s attractive proprietary technology platforms. A Novartis bid

Pfizer voluntarily pulled Bextra from the Canadian market in April 2005 upon the request of Health Canada. Despite disagreeing with the regulators position on the risk/benefit profile of

Animas is expected to operate as a stand-alone entity reporting through LifeScan, a Johnson & Johnson company offering blood glucose monitoring systems. The acquisition affords LifeScan immediate entry

The decision follows a review of data including the clinical, scientific, and epidemiological data establishing the safety and efficacy of the vaccine. “This decisive ruling marks an important

Interim findings following 24 weeks of dosing demonstrated potent antiviral activity for brecanavir in both PI-sensitive and PI-resistant HIV-infected adults. These data were presented at the 45th Interscience

Patients enrolled in the study, being conducted at two sites in the UK, will receive three months treatment with each of three different therapies – Bronchitol alone, both

The positive results from the trials bring the drug a step closer to a regulatory filing for marketing approval. The studies met their primary endpoints and showed that

Under terms of the agreement, AlgoRx stockholders own approximately 62% of the combined company on a pro forma basis and Corgentech stockholders own approximately 38%. The completion of